KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Other financing activities (2017 - 2019)

Neogenomics' Other financing activities history spans 5 years, with the latest figure at $8000.0 for Q4 2019.

  • For Q4 2019, Other financing activities changed N/A year-over-year to $8000.0; the TTM value through Dec 2020 reached $105000.0, changed 0.0%, while the annual FY2019 figure was $1.1 million, 83.85% up from the prior year.
  • Other financing activities reached $8000.0 in Q4 2019 per NEO's latest filing, down from $97000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $576000.0 in Q2 2018 to a low of -$112000.0 in Q3 2017.
  • Average Other financing activities over 4 years is $129666.7, with a median of $97000.0 recorded in 2016.
  • The largest YoY upside for Other financing activities was 15.46% in 2017 against a maximum downside of 15.46% in 2017.
  • A 4-year view of Other financing activities shows it stood at $97000.0 in 2016, then crashed by 215.46% to -$112000.0 in 2017, then soared by 614.29% to $576000.0 in 2018, then crashed by 98.61% to $8000.0 in 2019.
  • Per Business Quant, the three most recent readings for NEO's Other financing activities are $8000.0 (Q4 2019), $97000.0 (Q3 2019), and $576000.0 (Q2 2018).